HTN

A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination with Dapagliflozin in Participants with Chronic Kidney Disease and High Blood Pressure

Protocol Name: A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination with Dapagliflozin in Participants with Chronic Kidney Disease and High Blood Pressure Protocol #: D6972C00002 Indication: CKD & HTN GFR: 30-75 Principal Investigator: Ankit Mehta, MD Location: Landry Center, 411 N. Washington Ave, Suite #6000, Dallas, […]

A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination with Dapagliflozin in Participants with Chronic Kidney Disease and High Blood Pressure Read More »

A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination with Dapagliflozin on CKD Progression in Participants with CKD and High Blood Pressure.

Protocol Name: A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination with Dapagliflozin on CKD Progression in Participants with CKD and High Blood Pressure. Protocol #: D6972C00003 Indication: CKD & HTN GFR: 30-89 Principal Investigator: Ankit Mehta, MD Location: Landry Center, 411 N. Washington Ave, Suite #6000, Dallas, TX 75246

A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination with Dapagliflozin on CKD Progression in Participants with CKD and High Blood Pressure. Read More »